Barzegar M, Kaur G, Gavins F N E, Wang Y, Boyer C J, Alexander J S
Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.
Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA; Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.
Stem Cell Res. 2019 May;37:101421. doi: 10.1016/j.scr.2019.101421. Epub 2019 Mar 16.
Ischemia-reperfusion injury (I/RI), produced by an initial interruption of organ blood flow and its subsequent restoration, contributes significantly to the pathophysiologies of stroke, myocardial infarction, renal I/RI, intestinal I/RI and liver I/RI, which are major causes of disability (including transplant failure) and even mortality. While the restoration of blood flow is required to restore oxygen and nutrient requirements, reperfusion often triggers local and systemic inflammatory responses and subsequently elevate the ischemic insult where the duration of ischemia determines the magnitude of I/RI damage. I/RI increases vascular leakage, changes transcriptional and cell death programs, drives leukocyte entrapment and inflammation and oxidative stress in tissues. Therapeutic approaches which reduce complications associated with I/RI are desperately needed to address the clinical and economic burden created by I/RI. Stem cells (SC) represent ubiquitous and uncommitted cell populations with the ability to self-renew and differentiate into one or more developmental 'fates'. Like immune cells, stem cells can home to and penetrate I/R-injured tissues, where they can differentiate into target tissues and induce trophic paracrine signaling which suppress injury and maintain tissue functions perturbed by ischemia-reperfusion. This review article summarizes the present use and possible protective mechanisms underlying stem cell protection in diverse forms of ischemia-reperfusion.
缺血再灌注损伤(I/RI)是由器官血流的初始中断及其随后的恢复所产生的,它在很大程度上导致了中风、心肌梗死、肾缺血再灌注损伤、肠缺血再灌注损伤和肝缺血再灌注损伤的病理生理过程,而这些都是导致残疾(包括移植失败)甚至死亡的主要原因。虽然恢复血流是恢复氧气和营养需求所必需的,但再灌注往往会引发局部和全身的炎症反应,并随后加剧缺血损伤,其中缺血的持续时间决定了I/RI损伤的程度。I/RI会增加血管渗漏,改变转录和细胞死亡程序,导致白细胞滞留以及组织中的炎症和氧化应激。迫切需要能够减少与I/RI相关并发症的治疗方法,以应对I/RI造成的临床和经济负担。干细胞(SC)代表了普遍存在且未分化的细胞群体,具有自我更新和分化为一种或多种发育“命运”的能力。与免疫细胞一样,干细胞可以归巢并穿透缺血再灌注损伤的组织,在那里它们可以分化为靶组织并诱导营养旁分泌信号,从而抑制损伤并维持因缺血再灌注而受到干扰的组织功能。这篇综述文章总结了干细胞在多种形式的缺血再灌注中目前的应用以及潜在的保护机制。